A Phase II, Single-arm, Open-label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma
Latest Information Update: 06 Nov 2021
At a glance
- Drugs PBI 05204 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Phoenix Biotechnology
Most Recent Events
- 25 Jan 2020 Primary endpoint (overall survival) has not been met as per results presented at the 2020 Gastrointestinal Cancers Symposium
- 25 Jan 2020 Status changed to completed as per results presented at the 2020 Gastrointestinal Cancers Symposium
- 25 Jan 2020 Results presented at the 2020 Gastrointestinal Cancers Symposium